Diabetes Technology Highlights From ADA 2025
Sequel Medtech's new twiist AID system
A wide range of technology aimed at expanding choices for people with diabetes was presented at the American Diabetes Association's 2025 scientific conference.
Thousands of people passed through ADA's impressive exhibition hall, which featured the latest and greatest technology aimed at improving (and simplifying) diabetes management. Two newly available highlights included a novel automated insulin delivery (AID) system and updated continuous glucose monitoring (CGM) options for AID users. Future tech included a Beta Bionics patch pump and an implantable sensor designed to reduce CGM lag times.
Below is an overview of the innovative diabetes tech changing the face of diabetes care presented in Chicago.
Type 1 AID users get a boost from semaglutide
The first study of its kind presented evidence that a combination of AID and semaglutide (Ozempic for diabetes, Wegovy for weight management) can effectively help people with type 1 diabetes improve their time in range and lose weight.
In a six-month study, people with type 1 diabetes taking semaglutide lost an average of 18 pounds, improved their time in range (70-180 mg/dL), and saw less time below range.
The benefits were seen without increasing the risk of hypoglycemia or diabetic ketoacidosis. Participants did report side effects common with GLP-1s – mostly gastrointestinal issues.
Studies like this that show the benefits of therapies like GLP-1 drugs could help pave the way for FDA approval for their use in type 1 diabetes.
Sequel's twiist readies for launch
The new twiist AID system will be available in the U.S. starting July 7, Sequel Medtech announced. Twiist uses the Tidepool Loop algorithm embedded in a circular, tubed pump. The system is controlled via iPhone or Apple Watch and includes a manual bolus button on the pump.
The system's pump uses a novel way to measure insulin with sound waves – an approach that may allow for more accurate dosing and faster occlusion detection. The system is FDA-cleared for people with type 1 diabetes ages six and up.
The price is capped at $50 per month with insurance, the company said. The first month of supplies – including the pump and infusion sets – are free. Users will need a compatible CGM, such as the Abbott Freestyle Libre 3 Plus or Eversense 365.
Tandem’s t:slim X2 syncs with FreeStyle Libre 3 Plus
Tandem announced at ADA that its t:slim X2 insulin pump with Control-IQ+ AID tech is now compatible with Abbott’s FreeStyle Libre 3 Plus CGM sensor in the U.S. A limited rollout will lead to nationwide availability in late 2025.
The FreeStyle Libre 3 Plus sensor provides CGM readings every minute for 15 days. And the Control-IQ+ algorithm adjusts insulin every five minutes, while an auto-bolus feature can help adjust for missed meal boluses.
Minting a Beta patch pump
Beta Bionics said its in-development patch pump, called Mint, should be available in the U.S. sometime in 2027.
While the Mint will be compatible with iPhone and Android phones, the algorithm that drives the AID system is embedded into the pump itself, so no app or Bluetooth pairing is needed to change it.
The device uses disposable batteries, so there's no recharging time needed.
No out-of-pocket costs have been announced yet, but the company said that it plans to sell the Mint through insurers' prescription benefits (see our guide on navigating insurance with AID). Prescription benefit coverage should make the system less expensive and easier to obtain than if it were sold as a durable medical equipment benefit.
Reducing CGM lag
Continuous glucose monitoring helps keep blood sugar levels in range without the need for finger sticks, but the readings can lag 5-6 minutes behind a measurement taken from the bloodstream.
The Glucotrack blood glucose monitoring (CBGM) system is meant to eliminate that lag with an implantable device that could provide real-time readings by measuring glucose from blood instead of interstitial fluid, as CGM sensors do.
About the width and thickness of three nickels, the Glucotrack is meant to be implanted under the skin by a health care provider. The device is designed to provide readings for up to three years. The system is expected to enter long-term clinical trials over the next few years; the company hopes to launch the system in the U.S. sometime in 2028.